{'fraction_non_alphanumeric': 0.021739130434782608, 'fraction_numerical': 0.003952569169960474, 'mean_word_length': 5.371069182389937, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety of intranasal corticosteroids for allergic rhinitis in children

ABSTRACT Introduction Allergic rhinitis (AR) is a common chronic inflammatory disease of the nasal mucosa, affecting about 10–40% of children worldwide. Intranasal corticosteroids (INCSs) are the first-line anti-inflammatory drug in the treatment of pediatric AR. The systemic and local adverse effects of INCSs in children with AR should be assessed. Areas covered Randomized controlled trials (RCTs) reporting local and systemic adverse effects of INCSs in pediatric populations with AR were searched out of PubMed and Embase. Expert opinion Overall, INCSs displayed a favorable safety profile and high local-systemic balance of bioavailability with a low incidence of adverse events in the treatment of AR children. Nevertheless, the use of INCSs should be designed depending on one patient’s response and adverse effects. The benefits and risks of INCSs should be assessed to ensure the clinical efficacy and avoid the insidious events.